Drugs / SPL026
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05644093 | Jan → Apr 2023 | major depressive disorder | Small Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05553691 | Dec 2022 → Aug 2023 | major depressive disorder | Small Pharma Ltd | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT04673383 | Feb 2021 → Oct 2022 | major depressive disorder | Small Pharma Ltd | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPL026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05644093 ↗ |
| Known as | DMT fumarate | “AIM: The aim of Part A of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) profile of escalating doses of SPL026 (DMT...” PMID 38274414 ↗ Jan 2024 |
| Route | Intravenous | “SPL026 will be administered by IV injection” NCT04673383 ↗ |